One of the most acclaimed features of the
MYC
oncogene family (
MYC, MYCL1
and
MYCN
) is their prolific deregulation in cancer, which is often associated with poor prognosis and refractory disease. Multiple mechanisms can deregulate their expression in cancer, including chromosomal translocation, enhanced messenger ribonucleic acid (mRNA) and protein stability, gene amplification or enhancer hijacking. This MYC family of nuclear transcription factors regulates the expression of a multitude of target genes to control many critically important fundamental biological processes, including cellular proliferation, metabolism, apoptosis and embryonic development. MYC proteins are highly regulated, and many factors have been reported to control stability and activity via post‐translational modifications (PTMs). Decades of research into this potent oncogene family have revealed that while directly inhibiting MYC proteins in cancer remains challenging, there are multiple strategies to indirectly inhibit MYC in cancer. Developing such inhibitors to target MYC would have profound impact on patient care and outcome.
Key Concepts
The
MYC
family of oncogenes, composed of
MYC, MYCN
and
MYCL1
, encode nuclear basic helix‐loop‐helix transcription factors.
MYC family proteins contain highly conserved regions termed MYC boxes.
MYC regulates many transcriptional targets and can have wide‐reaching effects on the epigenome and total cellular RNA content.
MYC
is essential for cellular proliferation and is a potent oncogene when it is deregulated in cancer.
Deregulated, often elevated, MYC levels have been shown to drive tumourigenesis in many
in vivo
models.
MYC activity and stability is regulated by post‐translational modifications, including phosphorylation, ubiquitylation, SUMOylation and acetylation.